Literature DB >> 19287458

Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia.

William G Morice1, Dong Chen, Paul J Kurtin, Curtis A Hanson, Ellen D McPhail.   

Abstract

Lymphoplasmacytic lymphoma involving the bone marrow can be difficult to diagnose, and pathological features that predict the presence of associated Waldenström's macroglobulinemia have yet to be identified. To address these issues, marrow histology, immunohistochemistry, and flow cytometry were studied from 35 lymphoplasmacytic lymphoma cases that had comprehensive clinical assessment for Waldenström's macroglobulinemia. In all cases, the plasma cells were analyzed by a novel 6-color flow method. Both immunohistochemistry and flow cytometry were useful in identifying the lymphoid and plasmacytic disease components. In 19 cases, immunohistochemistry revealed an earlier unrecognized pattern of plasma cell infiltration in which they were physically separate from the lymphoid infiltrates. B-cell flow cytometry revealed monotypic cells in 96% of the cases. Approximately half of these were CD5 and/or CD23 positive, although none had features of chronic lymphocytic leukemia, and none of the B cells had flow cytometric features suggesting plasmacytic differentiation. In contrast, highly sensitive 6-color plasma cell flow cytometry revealed monotypic cells in 32 of the 35 cases; in 20 cases, the pattern of CD38 and CD138 coexpression detected was identical to that seen in plasma cell malignancies such as multiple myeloma. In 18 of these 20 lymphoplasmacytic lymphoma cases, these plasma cells were CD19 positive, distinguishing them from those of true plasma cell neoplasms, which are CD19 negative. It is interesting that the two lymphoplasmacytic lymphoma cases with CD19-negative plasma cells had an IgG isotype serum paraprotein. Apart from this, no other pathological correlates of the clinical or laboratory features of symptomatic Waldenström's macroglobulinemia were identified.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19287458     DOI: 10.1038/modpathol.2009.34

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  24 in total

1.  Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma.

Authors:  Shouying Du; Hooman H Rashidi; Dzung T Le; Thomas J Kipps; H Elizabeth Broome; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2010-04-23

2.  Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.

Authors:  B Paiva; M C Montes; R García-Sanz; E M Ocio; J Alonso; N de Las Heras; F Escalante; R Cuello; A G de Coca; J Galende; J Hernández; M Sierra; A Martin; E Pardal; A Bárez; J Alonso; L Suarez; T J González-López; J J Perez; A Orfao; M-B Vidríales; J F San Miguel
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

3.  Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Edward N Libby; Stephen M Ansell; M Lia Palomba; Kirsten Meid; Catherine A Flynn; Carly Leventoff; Christopher B Hergott; Tomasz Sewastianik; Elizabeth A Morgan; Ruben Carrasco; Jonathan R Fromm; Guang Yang; Zachary Hunter; Steven P Treon
Journal:  Blood Adv       Date:  2020-10-27

4.  Requirement of CXCL12-CXCR7 signaling for CD20(-) CD138(-) double-negative population in lymphoplasmacytic lymphoma.

Authors:  Naoki Wada; Jun-Ichiro Ikeda; Satoshi Nojima; Shin-Ichiro Tahara; Kenji Ohshima; Daisuke Okuzaki; Eiichi Morii
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

Review 5.  Immunophenotyping in multiple myeloma and related plasma cell disorders.

Authors:  Shaji Kumar; Teresa Kimlinger; William Morice
Journal:  Best Pract Res Clin Haematol       Date:  2010-09       Impact factor: 3.020

Review 6.  Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Authors:  Stephen M Ansell; Robert A Kyle; Craig B Reeder; Rafael Fonseca; Joseph R Mikhael; William G Morice; P Leif Bergsagel; Francis K Buadi; Joseph P Colgan; David Dingli; Angela Dispenzieri; Philip R Greipp; Thomas M Habermann; Suzanne R Hayman; David J Inwards; Patrick B Johnston; Shaji K Kumar; Martha Q Lacy; John A Lust; Svetomir N Markovic; Ivana N M Micallef; Grzegorz S Nowakowski; Luis F Porrata; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Carrie A Thompson; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; Morie A Gertz
Journal:  Mayo Clin Proc       Date:  2010-08-11       Impact factor: 7.616

7.  Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients.

Authors:  Linda N Dao; Curtis A Hanson; Angela Dispenzieri; William G Morice; Paul J Kurtin; James D Hoyer
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

8.  Recent advances in bone marrow biopsy pathology.

Authors:  Jon van der Walt
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

9.  Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Authors:  Aneel Paulus; Alak Manna; Sharoon Akhtar; Shumail M Paulus; Mayank Sharma; Marie V Coignet; Liuyan Jiang; Vivek Roy; Thomas E Witzig; Stephen M Ansell; John Allan; Richard Furman; Sonikpreet Aulakh; Rami Manochakian; Sikander Ailawadhi; Asher A Chanan-Khan; Taimur Sher
Journal:  Br J Haematol       Date:  2018-08-06       Impact factor: 6.998

Review 10.  [B-cell neoplasms with plasmacellular and plasmablastic differentiation].

Authors:  F Fend; L Quintanilla-Martínez
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.